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oxidation had little influence on the affinity of the 2 -GPI antibody complex for the membrane vesicles. We conclude that antibodies to 2 -GPI inhibit APC function specifically and contribute to a hypercoaguable state by disrupting specific protein-protein interactions induced by oxidation of PE containing membranes.
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INTRODUCTION
Antiphospholipid antibodies (APAs) are a family of autoantibodies that are often associated with an increased risk of thrombotic disease. This clinical association has been called the "antiphospholipid syndrome". These antibodies are defined by their ability to bind to negatively charged phospholipid, usually cardiolipin in a protein cofactor dependent fashion, in ELISA (APAs) or by their ability to inhibit phospholipid dependent coagulation assays (lupus anticoagulants or LAs). Suggestions of possible mechanisms by which these antibodies might contribute to hypercoaguability and thrombotic risk have been varied, as have the potential molecular targets of the antibodies 1; 2 (and references therein). We 3; 4 and others [5] [6] [7] have proposed that antibodies that inhibit the protein C anticoagulant pathway would be likely candidates as pathogenic antibodies. The protein C pathway serves as a major regulatory loop that limits thrombin generation through the inactivation of the cofactors, factor VIIIa and factor Va.
As little as a 50% inhibition of it's activity, either genetic or acquired, 8 has been found to be associated with an increased risk for thrombosis. Impairment of this pathway has been correlated with both venous and arterial disease, although the data for the latter is not as clear 9; 10 .
Many APAs are now recognized to be directed towards 2 -glycoprotein I ( 2 -GPI), either alone or in complex with negatively charged phospholipid 11 . Such antibodies have also been associated with thrombotic risk in some studies [12] [13] [14] [15] . 2 -GPI is a 50 kD plasma glycoprotein of unknown function that is capable of binding to anionic phospholipids. The coagulation reactions require negative surfaces to function 16 and it can be envisioned that phospholipid binding proteins could inhibit these reactions. Although there are some reports of direct 2 -GPI inhibition of activated protein C (APC) anticoagulant activity 17; 18 , in general, direct effects of 2 
-GPI on
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From the coagulation reactions are small 18; 19 , probably resulting from the low affinity of 2 -GPI for phospholipids in the presence of calcium 18; 20 . Antibody 2 -GPI complexes, however, have been found to have higher affinity for membrane than 2 -GPI alone 19; 21 . This may contribute to LA 19 and anti-APC activity 12; 22-24 . However, it is unclear how such antibodies would result in a net procoagulant state. Masking the membrane surface by antibody complexes would be predicted to mimic the effect of oral anticoagulants where all of the vitamin K dependent proteins lose affinity for membrane surfaces, leading to a net anticoagulant rather than a procoagulant state.
Recent investigations of the membrane requirements of the procoagulant vs anticoagulant
complexes have revealed a possible basis for specificity towards the anticoagulant complexes. We have reported that unlike the procoagulant complexes, optimal function of the APC anticoagulant complex requires the presence of phosphatidylethanolamine (PE), polyunsaturated fatty acids 16; 25 and phospholipid oxidation 4 . However, this membrane composition has little, if any, effect on the procoagulant reactions 4 . PE [26] [27] [28] and oxidation 29; 30 increase the binding of many APAs and the ability of at least some APAs to inhibit the APC complex specifically 3; 4; 16; 31 . Indeed, IgG purified from several anti-phospholipid syndrome patients inhibited only the lipid oxidation enhancement of APC activity, whereas IgG from nonthrombotic patients with APAs or LAs did not 31 . The potential clinical relevance of enhanced inhibition of APC function is suggested by the presence of increased oxidized lipids in the anti-phospholipid syndrome, 30 which we presume would normally enhance APC function . The presence of APAs would block this protective effect of phospholipid oxidation.
Phospholipid oxidation has also been implicated in the ability of APAs to recognize 2 -GPI when it is bound to the phospholipid surface 29; 32 . However, the impact of phospholipid For personal use only. on August 31, 2017. by guest www.bloodjournal.org From oxidation on inhibition of APC activity by anti-2 -GPI antibodies has not been reported. We have now used mouse monoclonal antibodies raised to purified 2 -GPI as a model for antibodies likely to be present in thrombotic anti-phospholipid syndrome patients. We demonstrate that antibodies directed toward several domains of 2 -GPI share the ability to specifically block the phospholipid oxidation dependent enhancement of APC activity.
MATERIALS AND METHODS
Proteins and Reagents--Human 2 -GPI was purified using ion exchange and heparin agarose chromatography as described previously 33 . This method does not entail the use of acidic conditions which may alter the structure of the 2 -GPI. Human APC, prothrombin, factor Xa, factors V and Va, protein S, the protein C-prothrombin gla-domain chimera (PC-PtGla) and the protein C chimera containing the first 22 amino acids of prothrombin [PC-Pt(1-22)], and the factor X activator from Russell's viper venom (X-CP) were all prepared as described previously 34 . Papain, bovine serum albumin, gelatin, and all chemicals were purchased from Sigma. MEP Hyper Cel was from Life Technologies, Chelex 100 resin was from Bio-Rad, and Spectrozyme-TH was from American Diagnostica. All phospholipids were from Avanti Polar Lipids Inc.
(Birmingham, AL). Phospholipids derived from bovine brain were utilized. Sulfo-NHS-LC-Biotin and ImmunoPure alkaline phosphatase conjugated Streptavidin were from Pierce.
Liposome Preparation--Vesicles were prepared by extrusion as described 25 using a 100-nm Nucleopore membrane. PS:PC vesicles were 20% phosphatidylserine (PS), 80% phosphatidylcholine (PC) and PE:PS:PC vesicles were 40% PE, 20% PS, 40% PC. Phospholipid Oxidation -Liposomes were oxidized with copper sulfate as previously described 4 .
Briefly, to 1 ml of liposomes (200 µg/ml) was added 1 µl of 10 mM CuSO 4 in a glass tube.
Suspensions were vortexed to introduce air, and the liposomes were incubated at 37° C. Standard oxidized liposomes were composed of brain-derived phospholipids oxidized for 20 h .
Preparation of monoclonal 2 -GPI antibodies -Five monoclonal antibodies (mAbs) (1519, 1522, 1527,1528 and 1529 ) were obtained from BALB/c mice immunized with human 2 -GPI by standard techniques 35 . Hybridomas were screened versus purified 2 -GPI on non--irradiated polyvinylchloride plates (Falcon). Antibodies for large scale production were produced using serum free media (Invitrogen Hybridoma-SFM). IgG from conditioned media was purified using MEP Hyper Cel chromatography according to the manufacture's instructions. All mAbs studied were IgG1 . The purified mAbs recognized 2 -GPI in solution, adsorbed on both plain or oxygenated polystyrene plates and in Western blots under non-reducing conditions. None detected 2 -GPI under reduced conditions. For some experiments, purified IgG was biotinylated using the Pierce reagents according to the manufacturer's directions.
Preparation of Fab Fragments -Fab fragments were prepared by digestion with papain. Purified IgG (6 mg/ml) was incubated with 30 µg/ml active papain (Sigma) in 0.15 M NaCl, 20 mM Tris HCl, pH 7.5 (TBS) , 2 mM EDTA, 2 mM DTT for 1 h at 37°C. The reaction was stopped with 10 mM iodacetamide followed by dialysis against TBS. The reaction mixture was applied to a MonoQ column (Amersham Biosciences) in the above buffer without DTT. The column retained the Fc fragment and undigested IgG but allowed the Fab fragments to pass through. The Fabs 7 were dialyzed against TBS and concentrated.
Characterization of mAb Binding to 2 -GPI -Standard ELISAs were used to estimate the binding affinity (K 1/2 ) for purified antibody binding to 2 -GPI. Briefly non--irradiated microtiter plates (Falcon) were coated with 100 µl of 1 µg/ml 2 -GPI in 0.15 M NaCl, 20 mM HEPES, pH 7.5 (HBS) overnight at 4°C. After blocking with 5% BSA in HBS, 100 µl of serial dilutions of purified mAbs were added. After 1 hr incubation, wells were washed and developed with horseradish peroxidase-labeled goat anti-mouse IgG followed by chromogenic substrate. All washes were with HBS containing 0.05% Tween. Of the five mAbs studied, four had K 1/2 's for binding between 50 and 150 ng/ml (0.3 -1 nM) and a fifth (#1528) had a K 1/2 for binding of >10 µg/ml (>60 nM) by this method.
The domain specificity of the antibodies was determined by competitive inhibition studies using 2 -GPI domain deletion mutants as inhibitors of binding to full length protein essentially as described 36 . The 2 -GPI deletion mutants used were kindly provided by Dr. G. Michael Iverson, La Jolla Pharmaceutical Company, San Diego, CA. Briefly, 2 -GPI was adsorbed onto Maxisorb plates (Nunc) and the plates blocked with HBS containing 2% non-fat dry milk. Dilutions of the 2 -GPI deletion mutants in HBS-2% milk followed by a fixed, appropriate dilution of biotinylated antibody were then added. After 1 hr incubation at room temperature, wells were washed with HBS-milk and incubated with alkaline phosphatase-streptavidin followed by alkaline phosphatase chromogenic substrate. Absorbance at 450 nm was measured in a V max Microplate Reader (Molecular Devices). Controls included full length 2 -GPI as inhibitor of binding and TBS-milk alone.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Coagulation Assays -Clotting times were determined by a modified factor Xa one-stage clotting assay using X-CP to activate factor X and an ST4 coagulometer (Diagnostica Stago) as described previously 4 . In the standard assay, normal pooled plasma (50 µl) was mixed with X-CP, phospholipid (10 µg/ml), in the presence or absence of APC (0.2 µg/ml) in a total volume of 150 µl. When present, IgG was at the final concentrations indicated. After 1 min of incubation at 37° C, 50 µl of 25 mM CaCl 2 was added to initiate clotting. X-CP was adjusted to obtain a 30 s clotting time in the absence of APC. Since the assay in the absence of APC is similar, but not equivalent, to those used clinically to define LA activity, anticoagulant activity observed under these conditions is considered "LA-like" rather than LA.
Measurement of APC Activity in Purified Systems--Factor Va (50 nM) was reacted with 2.5 pM APC, 20 µg/ml oxidized or nonoxidized PE:PS:PC vesicles, in the presence or absence of 20 nM protein S, 1 µM 2 -GPI and/or1 µM IgG at 37° C. At various times, the APC was inhibited by the addition of benzamidine HCl to 10 mM. After dilution, residual factor Va was determined by standard one-stage clotting assays using factor V-deficient plasma or by its activity in the prothrombinase complex as described previously 25; 34 .
Liposome-Protein Interactions Measured by Right Angle Light Scattering--Right angle light
scattering was performed as described previously 34 on an SLM 8000 fluorimeter (SLM Instruments, Urbana, IL) with the wavelength set at 320 nm. The liposome concentration was 10 µg/ml. Binding experiments were performed in HBS, with or without 2 mM CaCl 2 . Similar 9 profiles were obtained in experiments performed on at least two separate days.
RESULTS

Effect of anti-2 -GPI monoclonal antibodies on APC Anticoagulant
Activity --To test the functional ramifications of antibodies to 2 -GPI, we generated five mouse monoclonal antibodies and tested their ability to inhibit APC anticoagulant activity preferentially on oxidized PE containing phospholipids.When nonoxidized phospholipid vesicles were used, none of the anti-2 -GPI mAbs had a significant effect on APC activity ( Fig. 1, open and 1529 exhibited LA-like activity at higher antibody concentrations, lengthening the clotting time at least two fold when oxidized phospholipid was used, mAb #1527 showed no LA-like activity whether or not the phospholipid was oxidized. MAb #1519 showed minimal LA-like activity on oxidized vesicles. Mab #1528 showed [less than or equal to]25% inhibition on oxidized phospholipid and was not studied further. That both PE and oxidation are required for inhibitory activity of the anti-2 -GPI is shown in Fig 2 where antibody #1522 had no effect on APC activity on oxidized PS:PC vesicles.
It has been reported that in order to have APA or LA activity, anti-2 -GPI antibodies must be divalent 19-21; 37 . However, it has also been proposed that 2 -GPI exists in multiple conformations, one of which is stabilized by interaction with oxidized lipid, leading to exposure 10 of the pertinent antibody binding site(s) 29; 32; 38; 39 . This would imply that antibody binding would also stabilize the lipid binding conformer of 2 -GPI, leading to enhanced binding even in the absence of antibody divalency. To distinguish these possibilities, and since the membrane requirements for APC inhibition by APAs differ from those for LA activity 3 , Fab fragments of mAb #1522 were tested for their ability to inhibit APC function. Although the fragments were able to bind 2 -GPI with the expected affinity, they were unable to directly inhibit APC function on PE containing liposomes, whether or not they were oxidized (data not shown). Thus, the effectiveness of anti-2 -GPI antibodies on APC activity also depends on the bivalency conferred To determine what structures on APC may be necessary to be effectively inhibited by the anti-2 -GPI antibodies, we employed chimeric forms of APC that have proven useful in past structure-function studies 34 . We have previously shown that the activated PC-PtGla chimera, in which the gla domain of protein C is replaced with that of prothrombin, no longer requires the presence of protein S or PE for optimal activity 34 . Oxidation of PE containing vesicles also has only a minimal effect on the anticoagulant activity ( Fig. 3 ). In addition, this enzyme is only minimally affected by patient derived APAs 31 , suggesting it may be a useful therapeutic agent.
The chimera in which only the first 22 amino acids have been replaced by the homologous region of prothrombin (PC/ Pt(1-22) ) retains PE and protein S dependence 34 . The effect of mAb #1522 on these enzymes is illustrated in Figure 4 . The phospholipid oxidation dependent anticoagulant activity of APC and the PC/Pt(1-22) chimera was blocked by this antibody whereas the APC-PtGla is only slightly affected ( Fig. 4) . Similar inhibition profiles of APC and APC-PtGla were observed with all other mAbs (data not shown).
Epitope Specificity of the anti-2 -GPI mAbs --2 -GPI is composed of 4 homologous "sushi" domains and a 5 th non-canonical sushi domain where the phospholipid binding site is located [40] [41] [42] .
It has been suggested that antibodies directed to 2 -GPI with pathological function may be limited in their epitope specificity to a particular domain(s), although it is unclear which domain may be of functional significance 15; 36; 43 (and references therein). To determine the domain specificity of anti-2 -GPI mAbs that inhibit the oxidation dependent activity of APC, deletion mutants of 2 -GPI in the soluble phase were used as a soluble competitor with the intact 2 -GPI adsorbed to an ELISA plate for binding to each mAb (Fig. 5 ). The name of each construct indicates the domains of 2 -GPI that are present in the competing protein fragment. Each biotinylated antibody was present at 5 nM (0.7 µg/ml), a concentration that resulted in 40-60% maximal binding, depending on the antibody (Note: the K 1/2 's for 50% binding of directly biotinylated mAbs was not equivalent to that observed using a secondary antibody for development of the ELISAs indicated in Methods). It is evident that mAb #1529 (open squares) is capable of binding to isolated domain 1 of 2 -GPI as binding to the plate is abrogated by the presence of domain 1 in the soluble phase.
Similarly, mAb #1522 (open circles) shows competition for binding to 2 -GPI by any construct which contains domain 2 in the fragment. mAb #1527 (solid triangles) clearly reacts with domain 4. Although mAb #1519 (solid circles) binds isolated domain 1 (D1), the affinity is increased at least 10 fold when domain 2 is also present (data not shown). This may indicate an extended epitope that bridges domain 1 and 2 or mAb #1519 binds to an epitope whose conformation is greatly affected by the presence of the rest of the molecule. Thus, it is apparent that anti-2 -GPI antibodies that can inhibit the phospholipid oxidation dependent anticoagulant activity of APC are Effect of Monoclonal Antibody on APC Activity in Purified Systems --To be certain that the anti-2 -GPI was affecting the APC complex directly and not acting through another plasma component, the effect on factor Va inactivation by APC was investigated in a purified system ( Fig. 6 ). Under our conditions, 2 -GPI at 1 µM (the approximate concentration present in the plasma clotting assays) did not affect factor Va inactivation in the absence of antibody (upper panels). This is true whether or not protein S was present or whether the phospholipid was oxidized. When nonoxidized phospholipid was used as the membrane surface (left panels), the addition of antibody (lower panel) also did not affect factor Va inactivation under any conditions. When oxidized phospholipid was used (right panels), a different picture emerged when antibody was added (lower right panel). In the absence of 2 -GPI ["X" (-protein S) and solid triangles (+ protein S)], the antibody did not affect the reaction. However, in the presence of 2 
Effect of phospholipid composition and oxidation on 2 -GPI binding to vesicles -To determine
whether the observed functional effect of the 2 -GPI-antibody complex was due to enhanced For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 13 binding of 2 -GPI to the oxidized PE containing liposomes, light scattering studies were performed. In agreement with previous reports 37 , in the absence of calcium, 2 -GPI alone had moderately low affinity (~1.5 µM) which could be improved in the presence of oxidized PE to ~ 300 nM. However, when 2 mM calcium was added, although somewhat increased on oxidized PE containing vesicles, the binding was barely detectable up to 4 µM 2 -GPI (data not shown). In agreement with the studies of Harper, et.al. 18 , it seems unlikely that 2 -GPI would be a significant effector of coagulation reactions in the absence of antibody. Figure 2 ). Fab fragments of mAb #1522 had no affect on the binding of 2 -GPI to the vesicles under any conditions (data not shown).
DISCUSSION
The studies presented here, based on the membrane requirements of the anticoagulant For personal use only. on August 31, 2017. by guest www.bloodjournal.org From complex, may help explain how apparently nonspecific membrane or phospholipid binding of antibody-2 -GPI complexes can have specific functional consequences. Several investigators have noted a correlation of antibodies to 2 -GPI and the development of resistance to APC 23 and/or thrombosis 12; 15 . Because of a growing belief that antibodies to 2 -GPI with LA activity are more strongly associated with thrombosis that those of other specificities, assays have recently been developed to better identify this population 44; 45 . However, no mechanism is proposed to account for these in vitro anticoagulant populations becoming procoagulant in vivo. In addition, as seen in Figure 1 , anti-2 -GPI mAbs with little or no LA-like activity in the absence of APC (note: our assay most closely resembles the dRVVT clotting assay) can have significant activity when APC activity is monitored. Previous studies of 2 -GPI or 2 -GPI-antibody complex binding have been predicated on the assumption that 2 -GPI and the coagulant and anticoagulant proteins shared similar phospholipid specificity 18-20; 46; 47 . The impact of PE and/or phospholipid oxidation under physiological conditions of calcium and ionic strength were not tested. Other studies 7; 12; 17; 24; 48 have investigated the role of anti-2 -GPI on APC anticoagulant activity directly. However, these studies were compromised due to the choices of lipid (PS:PC) or complex phospholipid mixtures (thromboplastins or platelin) and/or the lack of control for oxidation. Furthermore, these studies could not explain the specificity which could lead to thrombosis.
In previous studies, IgG purified from thrombotic patients exhibited oxidation, PE dependent inhibition of APC anticoagulant function 4; 31 . Further studies have indicated the majority of these antibodies are 2 -GPI dependent (data not shown). The mouse monoclonal antibodies described here, raised to purified 2 -GPI, exhibited similar properties. That is, inhibition of APC function required the presence of PE, oxidation of the phospholipid and could For personal use only. on August 31, 2017. by guest www.bloodjournal.org From be observed at concentrations below that necessary for significant LA-like activity. Very recent studies of de Laat, et al 43 indicate that 2 -GPI antibodies directed to a specific epitope on domain one involving Gly40 and Arg43 are most strongly associated with thrombosis. We have not observed a requirement for domain specificity in the monoclonal antibodies with specific APC inhibitory activity. Some patients with thrombosis (with or without LA activity) did not have specificity for this epitope in the de Laat, et. al. report. It is possible these patients may have antibodies that inhibit APC in an oxidation, PE dependent manner similar to the monoclonals described here. It is also not necessary to invoke lattice formation by heterogeneous anti-2 -GPI antibodies in patient samples to explain inhibition of the anticoagulant complex. It would appear that divalency, rather than specific orientation of 2 -GPI on the membrane is sufficient for APC inhibitory activity. In contrast, specific orientation such as that observed by de Laat, et.al. seem to be important for LA activity.
The above arguments would favor the concept that any antibody to 2 -GPI should inhibit APC function and hence be prothrombotic. This may not be the case as illustrated by mAb #1528.
Although it binds with high affinity based on the functional assay (although inhibition is partial, the plateau is reached at low concentration, see Fig. 1 ), the inhibition of APC attained is minimal, possibly due to direct binding to one or more complex constituent, but incomplete steric hindrance of the APC complex.
A potential hypothesis to explain the selective inhibition of APC activity would be that PE and phospholipid oxidation increase the membrane binding affinity of the 2-GPI-antibody complex. Since the APC anticoagulant complexes benefit selectively from the PE and oxidation effects, increased 2-GPI-antibody complex affinity for the shared sites would lead to selective It has been suggested that 2 -GPI interacts directly with protein S 49 . Although those authors propose a different mechanism for the prothrombotic effect of anti-2 -GPI antibodies, such molecules might also interfere with protein S -APC interaction as suggested here in the purified system ( Figure 6 ). However, the protein S -2 -GPI interaction was not oxidation, PE or phospholipid dependent. Unlike the purified system which is only minimally dependent on protein S, in plasma the anticoagulant activity of APC is almost totally dependent on protein S stimulation 34 . Even so, although the prolongation in protein S deficient plasma by high concentrations of APC was slight, the addition of mAb shortened the clotting time (data not shown). This would be expected if the antibody was not enhancing a direct 2 -GPI -protein S interaction.
At this point in time, it is not known whether the 2 -GPI-anti-2 -GPI complexes physically compete with the APC or another component of the complex for the membrane surface or disrupt an interaction within the complex. We favor the concept that oxidation of PE containing membranes induces specific interactions between the proteins of the anticoagulant complex. Disruption of these specific protein-protein interactions by the 2 -GPI-antibody complexes would lead to specific inhibition. In the purified systems, APC function is For personal use only. on August 31, 2017. by guest www.bloodjournal.org From significantly more inhibited in the presence of protein S than in its absence ( Fig 6) , even though the affinity of APC for factor Va-phospholipid is tighter in the presence of protein S than its absence 34 . The PC-PtGla chimera was not affected by the antibody complex, even though the chimera and native APC have similar affinities for these membranes 34 . It is unlikely the 2 -GPIantibody complexes would compete for the membrane surface with one but not the other.
We have previously shown that the titer of LA-like activity and the APC inhibitory activity described here do not necessarily correlate 3 . In the case of an individual with anti-2 -GPI, or possibly antibodies with other specificities, these complexes will bind to the entire membrane more or less equivalently. However, even if some competition occurs with the procoagulant reactions in the non-PE containing regions, significant procoagulant activity would remain due to the high concentrations and membrane affinities of these proteins. It is well documented that a 50% decrease in APC activity can result in a hypercoaguable state 8 . Therefore, by blocking the oxidation dependent enhancement of APC activity even though the non-oxidation dependent activity remains mostly intact, the balance can be shifted back toward a hypercoaguable state.
In terms of overall regulation of coagulation, we envision that cells become activated by strong agonists and expose procoagulant membrane phospholipids. Leukocytes are recruited to the injury site, release a variety of potent oxidants, eventually transforming the nature of the membrane surface creating sites that optimize APC anticoagulant activity. Normally, this serves to dampen the coagulant response and limit thrombus growth. When antibody-2-GPI complexes are present, they also interact within these domains and through protein-protein interactions with components of the APC anticoagulant complex, eliminate the selective enhancement of the anticoagulant function. If there has not been an injury or inflammatory reaction resulting in an oxidized surface, such antibody complexes may not be prothrombotic, possibly accounting for the There is some support for the overall scheme outlined above. In mice deficient in Pselectin and hence with impaired leukocyte recruitment, thrombus formation in response to deep arterial injury is increased relative to controls despite having the opposite effect on the vascular proliferative response following the injury 50 . This would be consistent with an anticoagulant effect elicited by leukocyte recruitment. Obviously, in such complex models alternative mechanisms could account for the observed response. Also lacking in this system is any indication of whether antibody-2-GPI complexes inhibit the apparent leukocyte dependent dampening of the thrombotic response. For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
